Send us Fan MailImagine stepping into the world of pharmacovigilance with Sue Rees, founder of Sue Rees Consultancy, who has graced the industry for over three decades. As we stroll down memory lane, we relive Sue's fascinating progression from her rookie days at Smith, Kline & French's adverse events department to her critical QPPV roles across the continents. We unravel the compelling narrative of how Brexit prompted Sue's entrepreneurial journey and her contributions to the education sector.Together with Sue, we traverse through the contrasting paths taken by the FDA and the EMA, and delve into the divergent experiences of countries at varying stages of their PV journey. We also contemplate the ripple effects of the UK's EMA exit on its international reputation. Tune in as we contemplate the future of safety in organizations and the potential role of AI in diminishing manual case processing. We investigate the heightened emphasis on safety brought forth by the COVID-19 pandemic and explore effective delegation of responsibility within organizations. Let's tap into Sue's wisdom on the emerging trends of data gathering and legislation, and how the evolving regulations are reshaping career roles. As we peer into the future, we'll consider how technology could revolutionize data gathering, allowing us to concentrate on the clinical and scientific aspects of legislation.

Send us Fan MailFeeling intimidated by the thought of AI transforming the world of pharmacovigilance? Join us as we sit down with Fraser McCullum, founder of Imagine Pharmacovigilance Limited, who has spent over 20 years navigating the dynamic landscape of this industry. From his time as a bench scientist to establishing his own company, Fraser offers an insightful perspective on case processing to signal detection, and the future of risk management in pharmacovigilance. Our conversation also delves into the feared impact of AI on the conservative PV industry. Fraser clears the air on some widespread misconceptions and provides reassurances about the supposed threat of job loss due to AI. We also explore the increasing role of regulatory oversight in the age of Software as a Service (SaaS), and discuss how pharma companies must adapt to this new reality.We wrap up with an in-depth discussion on the future of pharmaceutical safety – from nuanced differences in ingestion methods to the rise in stimulated reporting due to Covid-19. Fraser underscores the critical necessity for collaboration within PV, the pitfalls of generic solutions, and the delicate balance of prudent spending and innovative problem-solving. Don't miss this opportunity to tap into Fraser’s vast knowledge and insights - perfect for anyone involved or interested in the world of pharmacovigilance.

Send us Fan MailWelcome to Truliant Talks, your definitive source for the world of pharmacovigilance amd risk management.As we enter an era defined by innovation and technological advancement, Truliant Talks is proud to announce a new podcast series, 'Innovation and the Future of Pharmacovigilance'.This holistic series will tackle every perspective of pharmacovigilance - from the role of regulators, the importance of vendors, to embracing AI, data privacy, and much more.We'll feature leaders, innovators, and visionaries - the people shaping pharmacovigilance. They'll share their experiences, insights, tips, and perhaps, a guess or two about what the future holds.Join us on this journey. The future begins on the 30th of October, available on all major podcast platforms.